CRDF

Cardiff Oncology, Inc.

1.24 USD

Last updated Dec 10, 17:12 UTC

Yesterday HIGH

$1.31

Yesterday LOW

$1.26

52w HIGH

$2.79

52w LOW

$0.94

EPS

-0.22

PE

-5.64

Next Earnings

Feb 29, 2024

Overview News Insider Transactions Government Trades

Cardiff Oncology, Inc. stock is up 24% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 35% of the previous 19 December’s closed higher than November.

Cardiff Oncology, Inc. develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

San Diego, United States Of America

Website

cardiffoncology.com

Benzinga Newsdesk

Tue Mar 28, 2023

Cardiff Oncology Has Dosed First Patient In The Phase 2 ONSEMBLE Trial Of Onvansertib Assessing Difference In Response And Onvansertib's Contribution To Standard Of Care For The Second-Line Treatment Of KRAS/NRAS-Mutated Metastatic Colorectal Cancer
richadhand@benzinga.com

Tue Mar 7, 2023

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $15

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and raises the price target from $14 to $15.
Michael Horton

Thu Mar 2, 2023

Cardiff Oncology FY22 EPS $(0.89), Sales $386K
Benzinga Insights

Tue Feb 28, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Newsdesk

Thu Nov 3, 2022

Cardiff Oncology Q3 EPS $(0.20) Down From $(0.17) YoY, Sales $93.00K Up From $86.00K YoY

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.20) per share. This is a 17.65 percent decrease over losses of $(0.17) per share from the same period last year. The company reported $93.00 thousand in
Lisa Levin

Wed Oct 12, 2022

Clear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively Buying

US gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Lisa Levin

Tue Sep 20, 2022

Hoth Therapeutics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

The Dow Jones jumped by around 197 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga Insights

Mon Sep 19, 2022

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Newsdesk

Fri Sep 16, 2022

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $14

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target from $22 to $14.
Lisa Levin

Wed Sep 14, 2022

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.